Alimera Sciences Announces Launch of Iluvien for Uveitis in Spain

Alimera Sciences announced that Alimera Sciences Europe Limited, its Ireland-based European subsidiary, will launch Iluvien for noninfectious posterior uveitis in Spain, through its distribution partner, Brill Pharma (Brill). Brill has received a positive resolution for the pricing and reimbursement approval for Iluvien for prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye from the Spanish Ministry of Health.

“We are pleased to begin 2022 with this launch in Spain, our third major market to add the posterior uveitis indication,” said Rick Eiswirth, President and Chief Executive Officer of Alimera. “Iluvien is the first and only treatment to deliver drug for up to thirty-six months, reducing the recurrence of symptoms of disease, and enabling patients to see better, longer with fewer injections.”

Iluvien is a sustained release intravitreal implant indicated in Europe for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies and for prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIPU).